Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2024 | Comparing surveillance and surgery for the management of desmoid tumors

Joanna Szkandera • 17 Sep 2024
ESMO 2024
Sarcoma Nirogacestat

Joanna Szkandera, MD, Medical University of Graz, Graz, Austria, discusses the evolving treatment approach for desmoid tumors, highlighting the recent FDA approval of nirogacestat. Prioritizing active surveillance for asymptomatic patients, especially when the tumor is located outside the abdomen, has been agreed on as the best course of action in these patients. This approach underscores a shift towards less invasive management unless symptoms or tumor location necessitate surgical intervention. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Joanna Szkandera

Sarcoma trials at ESMO 2024: MEGAMOST, AXAGIST, and more
7:47
Sarcoma trials at ESMO 2024: MEGAMOST, AXAGIST, and more
Joanna Szkandera • 17 Sep 2024

Related Videos

Using spatial RNA-protein profiling to identify ADC targets in LMS
1:20
Using spatial RNA-protein profiling to identify ADC targets in LMS
Carlos Torrado • 1 Jun 2026
ctDNA monitoring for recurrence in bone and soft tissue sarcoma
0:58
ctDNA monitoring for recurrence in bone and soft tissue sarcoma
Maggie Zhou • 1 Jun 2026
ctDNA improves detection and prognostication of sarcoma recurrence
0:45
ctDNA improves detection and prognostication of sarcoma recurrence
Maggie Zhou • 1 Jun 2026
Sarcoma highlights at ASCO 2026: SARC-041, PEAK, and RINGSIDE
1:00
Sarcoma highlights at ASCO 2026: SARC-041, PEAK, and RINGSIDE
Maggie Zhou • 1 Jun 2026
The content of VJOncology is intended for healthcare professionals